Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
GeoVax will use its MVA-VLP vaccine platform to design and construct the vaccine candidate and BravoVax will provide further development
January 28, 2020
By: Kristin Brooks
GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, and BravoVax, a vaccine developer in Wuhan, China, have signed a Letter of Intent to jointly develop a vaccine against the coronavirus (known as 2019-nCoV). GeoVax will use its MVA-VLP vaccine platform to design and construct the vaccine candidate using genetic sequences from the ongoing coronavirus outbreak originating in Wuhan, China. BravoVax will provide further development, including testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities. GeoVax’s Modified Vaccinia Ankara (MVA) platform technology is built on a 5th generation MVA vector system that is improved for high expression and stable transgenes during manufacture. Similar to its parent MVA, it has the advantage of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells for vaccination, thus inherently safe. Importantly, MVA vaccines elicit protective T cell as well as antibody responses in animals and humans. The GeoVax MVA platform can be combined with the potent immunogenicity of Virus Like Particles (VLPs) or be used to express proteins in their native conformations, enabling construction of vaccine candidates that induce full protection after a single dose. David Dodd, GeoVax president and chief executive officer, said, “Serious infectious disease epidemics such as the current coronavirus outbreak require rapid and effective response in order to minimize the detrimental impact on populations at risk. We are extremely pleased to begin working with BravoVax on this important and critical project, focused on minimizing the threat and impact of 2019-nCoV. The GeoVax technology and expertise has previously demonstrated success in addressing various infectious disease threats, based upon our novel MVA-VLP platform and expertise. With BravoVax located at the epicenter of this outbreak and their respective expertise, we feel confident towards advancing our vaccine candidate into clinical development in a timely manner, providing a critical tool in addressing the new coronavirus threat.” Wu Ke, BravoVax founder and chief executive officer, said, “As an established human vaccine developer, BravoVax is committed to utilizing its resources and network of connections within the Chinese virology, epidemiology, and regulatory communities to address this new threat to public health. Our physical location in Wuhan, essentially ‘Ground Zero’ for the novel coronavirus outbreak, gives us even greater incentive to be a part of an effective solution. We are excited by the opportunity to partner with GeoVax in leveraging their proven MVA-VLP vaccine platform to address this crisis. We look to collaborate closely with them in moving their vaccine candidate through pre-clinical and clinical testing in the most expeditious way possible in our aim to bring a safe and effective vaccine to those at risk for acquiring this infection.” Coronaviruses are common in many species of animals, including mammals, avians, and bats. In rare occasions, these viruses can evolve to cross the animal species and infect humans. They can quickly spread from person to person, resulting in lethal, yet rare, respiratory infections.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !